Shionogi makes first filing for QuatRx's lead product
This article was originally published in Scrip
Executive Summary
Shionogi's US subsidiary has submitted a US new drug application for Ophena (ospemifene), marking the first regulatory filing worldwide for QuatRx Pharmaceuticals' most advanced development project.